These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 27193436)

  • 1. Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.
    Lu R; Zhang Y; Zhu X; Fan Z; Zhu S; Cui M; Zhang Y; Tang F
    Int Urol Nephrol; 2016 Sep; 48(9):1499-509. PubMed ID: 27193436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.
    Badve SV; Palmer SC; Strippoli GFM; Roberts MA; Teixeira-Pinto A; Boudville N; Cass A; Hawley CM; Hiremath SS; Pascoe EM; Perkovic V; Whalley GA; Craig JC; Johnson DW
    Am J Kidney Dis; 2016 Oct; 68(4):554-563. PubMed ID: 27138469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease: A Systemic Review and Meta-Analysis.
    Yuan CY; Gao YC; Lin Y; Liu L; Shen XG; Zou WL; Wang MM; Shen QQ; Shao LN; Liu YM; Zhang JW; Pan ZH; Zhu Y; Yu JT; Yu XG; Zhu B
    Am J Nephrol; 2024; 55(1):1-17. PubMed ID: 37793348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials.
    Ng KP; Arnold J; Sharif A; Gill P; Townend JN; Ferro CJ
    J Renin Angiotensin Aldosterone Syst; 2015 Sep; 16(3):599-613. PubMed ID: 25784710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
    Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M
    Am J Kidney Dis; 2016 Oct; 68(4):591-598. PubMed ID: 27265777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
    Hammer F; Malzahn U; Donhauser J; Betz C; Schneider MP; Grupp C; Pollak N; Störk S; Wanner C; Krane V;
    Kidney Int; 2019 Apr; 95(4):983-991. PubMed ID: 30712923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
    Mavrakanas TA; Giannetti N; Sapir-Pichhadze R; Alam A
    Cardiorenal Med; 2020; 10(1):32-41. PubMed ID: 31665724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction: A meta-analysis of randomized controlled trials.
    Xu Y; Qiu Z; Yang R; Wu Y; Cheng X
    Medicine (Baltimore); 2018 Dec; 97(51):e13690. PubMed ID: 30572494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis.
    Berbenetz NM; Mrkobrada M
    BMC Cardiovasc Disord; 2016 Dec; 16(1):246. PubMed ID: 27905877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis.
    Chen Q; Liang Y; Yan J; Du Y; Li M; Chen Z; Zhou J
    Diabetes Res Clin Pract; 2023 Jan; 195():110210. PubMed ID: 36509181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis.
    Chen KT; Kang YN; Lin YC; Tsai IL; Chang WC; Fang TC; Wu MS; Kao CC
    Clin J Am Soc Nephrol; 2021 Jun; 16(6):916-925. PubMed ID: 34117083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: A meta-analysis.
    Zhu Y; Liu Y; Cai R; Zheng D; Liang X; Tao M; Jin J; Li Y; He Q
    Medicine (Baltimore); 2021 Feb; 100(8):e24882. PubMed ID: 33663116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease.
    Folkerts K; Millier A; Smela B; Olewinska E; Schmedt N; Mernagh P; Kovesdy CP
    J Nephrol; 2023 May; 36(4):1135-1167. PubMed ID: 36422853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid antagonists in chronic kidney disease.
    Dhaybi OA; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Jan; 26(1):50-55. PubMed ID: 27753685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Alexandrou ME; Papagianni A; Tsapas A; Loutradis C; Boutou A; Piperidou A; Papadopoulou D; Ruilope L; Bakris G; Sarafidis P
    J Hypertens; 2019 Dec; 37(12):2307-2324. PubMed ID: 31688290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis.
    Vukadinović D; Lavall D; Vukadinović AN; Pitt B; Wagenpfeil S; Böhm M
    Am Heart J; 2017 Jun; 188():99-108. PubMed ID: 28577687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Tsukamoto S; Morita R; Yamada T; Urate S; Azushima K; Uneda K; Kobayashi R; Kanaoka T; Wakui H; Tamura K
    Diabetes Res Clin Pract; 2022 Dec; 194():110161. PubMed ID: 36403681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.